First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, 1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S. Helps protect against more serotypes of pneumococcal disease than any other conjugate vaccine Builds on Pfizer’s more than 20-year legacy and innovation in .
NEW YORK and MAINZ, GERMANY, May 28, 2021 - Pfizer Inc.(Nasdaq: BNTX) today announced that the Conditional Marketing Authorization (CMA) for COMIRNATY in the European Union (EU) has been expanded to include
Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Pfizer and BioNTech to Supply the European Union With up to 1 8 Billion Additional Doses of COMIRNATY® pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.